CN107937372A - The Nattokinase that a kind of acid resistance improves - Google Patents

The Nattokinase that a kind of acid resistance improves Download PDF

Info

Publication number
CN107937372A
CN107937372A CN201711376850.1A CN201711376850A CN107937372A CN 107937372 A CN107937372 A CN 107937372A CN 201711376850 A CN201711376850 A CN 201711376850A CN 107937372 A CN107937372 A CN 107937372A
Authority
CN
China
Prior art keywords
mutant
nattokinase
recombinant bacterium
pro
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201711376850.1A
Other languages
Chinese (zh)
Other versions
CN107937372B (en
Inventor
周哲敏
刘中美
周丽
崔文璟
郭军玲
赵菡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangnan University
Original Assignee
Jiangnan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangnan University filed Critical Jiangnan University
Priority to CN201711376850.1A priority Critical patent/CN107937372B/en
Publication of CN107937372A publication Critical patent/CN107937372A/en
Application granted granted Critical
Publication of CN107937372B publication Critical patent/CN107937372B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention discloses the Nattokinase that a kind of acid resistance improves, belong to protein engineering.Nattokinase Q59E the Y217K N218D and Y217K that the present invention obtains, in acid condition, the wilder enzyme of stability of Q59E Y217K N218D and Y217K are improved largely.Nattokinase mutant Q59E Y217K N218D and Y217K provided by the invention can preferably tackle gastropore extreme acid condition, improve application value of the Nattokinase as treatment cardiovascular and cerebrovascular disease oral drugs.

Description

The Nattokinase that a kind of acid resistance improves
Technical field
The present invention relates to the Nattokinase mutant that a kind of acid resistance improves, belong to protein engineering.
Background technology
Nattokinase (NK, EC3.4.21.62) is japanese traditional food natto during the fermentation by Bacillus subtilis natto from Traditional Japanese Food A kind of serine protease that (Bacillus natto) is produced, compared to commercially available thrombolytic drug, has the effect of efficient thrombus dissolving, It is most potential fibrinolytic protein enzyme.Therefore developed and had broad application prospects for orally available medicine, yet with stomach The extreme acid condition in road, seriously limits the commercial Application of the enzyme.Existing Nattokinase acid resistance is poor, is badly in need of a kind of acidproof Property the Nattokinase mutant that improves, to adapt to the extreme acid condition of gastropore, promote Nattokinase opening as thrombolytic drug Hair and application.
The content of the invention
First purpose of the present invention is to provide the Nattokinase mutant that a kind of acid resistance improves, the mutant be by Multiple amino acid sites of Nattokinase of the amino acid sequence as shown in SEQ ID NO.1 are mutated.
In one embodiment of the invention, the mutant is for shown in SEQ ID NO.1 by amino acid sequence The 59th of Nattokinase, the 217th, one or more amino acid sites of the 218th are mutated.
In one embodiment of the invention, the mutant is for shown in SEQ ID NO.1 by amino acid sequence 217th tyrosine of Nattokinase sports lysine.
In one embodiment of the invention, the mutant is for shown in SEQ ID NO.1 by amino acid sequence 59th glutamine of Nattokinase sports glutamic acid, while the 217th tyrosine is sported lysine and 218 days Winter acid amides sports aspartic acid, obtains combination mutant Q59E-Y217K-N218D.
Second object of the present invention is to provide a kind of recombinant bacterium for expressing Nattokinase mutant.
In one embodiment of the invention, the construction method of the recombinant bacterium is：By the base of Nattokinase mutant Because being connected on carrier pET24a, with e. coli bl21 position host, recombinant bacterium is built.
Third object of the present invention is to provide a kind of method for expressing Nattokinase mutant, comprises the following steps that：
(1) recombinant bacterium is inoculated in the LB culture mediums containing kanamycins, 35-38 DEG C, the training of 150-250r/min shaken overnights Support and obtain seed liquor.
(2) expression that seed liquor is inoculated in the concentration containing kanamycins respectively by the inoculum concentration that mass fraction is 1-2% is trained Support in base, 35-38 DEG C, 150-250r/min shaken cultivations to OD600During to 0.6-0.8, derivant IPTG is added, in 15-18 DEG C Induce the expression of 18-24h Nattokinase mutant.
In one embodiment of the invention, the concentration of the kanamycins is 80-120 μ g/mL.
In one embodiment of the invention, the derivant IPTG to 0.05-0.2mM.
In one embodiment of the invention, the derivant IPTG to 0.1mM
In one embodiment of the invention, the expression culture medium is TB culture mediums, and the TB nutrient media componentses are： Tryptone 10-14g/L, yeast extract 20-26g/L, glycerine 3-8g/L, KH2PO42.0-2.6g/L, K2HPO4· 3H2O15.8-16.8g/L, CaCl20.15-0.25g/L, surplus are water.
In one embodiment of the invention, the purge process of the Nattokinase：After bacterial cell disruption being recombinated, collect Supernatant, after supernatant membrane filtration, at 2-6 DEG C, with the isolated pure enzyme liquid of Nattokinase mutant of nickel column centrifugal column.
Beneficial effects of the present invention：Nattokinase mutant Q59E-Y217K-N218D provided by the invention has more preferable Acid stability, after especially handling 4h under the conditions of pH4.0, wild type WT only remains about 25% enzyme activity, and mutant Y217K is protected 67% enzyme activity is held, mutant Q59E-Y217K-N218D remains to retain about 80% enzyme activity, Nattokinase is greatly improved Acid resistance.Therefore, Nattokinase mutant Y217K, Q59E-Y217K-N218D provided by the invention will more adapt to take orally, can be more Good reply gastropore extreme acid condition.
Brief description of the drawings
The remnant enzyme activity of the wild enzymes of Fig. 1 (WT) and mutant after processing 4h under the conditions of pH4.0.
Embodiment
LB nutrient media componentses are：Peptone 8-12g/L, yeast extract 4-6g/L, NaCl 8-12g/L
TB nutrient media componentses are：Tryptone 10-14g/L, yeast extract 20-26g/L, glycerine 3-8g/L, KH2PO42.0-2.6g/L, K2HPO4·3H2O 15.8-16.8g/L, CaCl20.15-0.25g/L
The definition of enzyme activity：In 25 DEG C, pH8.0, concentration of substrate 0.4mM, 1min, by 1 μm of o l suc-AAPF-pNA Change into the enzyme amount needed for 1 μm of ol pNA and be defined as an enzyme activity unit.
Enzyme activity determination method：(contain 0.1mMCaCl in 100mM pH8.0Tris-HCl buffer solutions2), with artificial synthesized Suc-AAPF-pNA is substrate, reacts 3min at 25 DEG C, and generation paranitroanilinum (pNA) is measured according to the absorption value of 405nm Concentration mensuration enzyme activity.
PH stability determines：Residual enzyme is measured after wild enzyme WT and mutant are retained 4h in 4 DEG C in pH4 buffer solutions It is living, highest enzyme activity is defined as 100%, obtains pH stability block diagrams.
The structure of 1 Nattokinase single mutant of embodiment and double-mutant
(1) structure of single mutant Q59E
Using pET24a-pro-NK as masterplate, with primer shown in table 1 under the conditions of shown in table 5, PCR obtains carrying coding The recombinant vector of Q59E mutant genes, obtains plasmid pET24a-pro-NK/Q59E.
1 mutant Q59E primers of table
PCR product is analyzed and identified by 1.0% agarose gel electrophoresis；It is again that PCR product is pure with DNA purification kits Change, finally use QuichCutTmDpnI digests 5h in 37 DEG C and removes the template plasmid to methylate, is transferred to BL21 escherichia coli hosts, Recombinant bacterium is named as BL21/pET24a-pro-NK/Q59E.
(2) structure of single mutant Y217K
Using pET24a-pro-NK as masterplate, with primer shown in table 2 under the conditions of shown in table 5, PCR obtains carrying coding The recombinant vector of Y217K mutant genes, obtains plasmid pET24a-pro-NK/Y217K.
2 mutant Y217K primers of table
PCR product is analyzed and identified by 1.0% agarose gel electrophoresis；It is again that PCR product is pure with DNA purification kits Change, finally use QuichCutTmDpnI digests 5h in 37 DEG C and removes the template plasmid to methylate, is transferred to BL21 escherichia coli hosts, Recombinant bacterium is named as BL21/pET24a-pro-NK/Y217K.
(3) structure of single mutant N218D
Using pET24a-pro-NK as masterplate, with primer shown in table 3 under the conditions of shown in table 5, PCR obtains carrying coding The recombinant vector of N218D mutant genes, obtains plasmid pET24a-pro-NK/N218D.
3 mutant N218D primers of table
PCR product is analyzed and identified by 1.0% agarose gel electrophoresis；It is again that PCR product is pure with DNA purification kits Change, finally use QuichCutTmDpnI digests 5h in 37 DEG C and removes the template plasmid to methylate, is transferred to BL21 escherichia coli hosts, Recombinant bacterium is named as BL21/pET24a-pro-NK/N218D.
(4) structure of double-mutant Q59E-N218D
Using pET24a-pro-NK as masterplate, with primer shown in table 1 under the conditions of shown in table 5, PCR obtains carrying coding The recombinant vector of Q59E mutant genes；Using small amount plasmid extraction kit, upper step extracts pET24a- to specifications Pro-NK/Q59E plasmids, then using pET24a-pro-NK/Q59E as template, with primer shown in table 3 under the conditions of shown in table 5, PCR Obtain carrying the recombinant vector of coding Q59E-N218D double-mutant genes, plasmid is named as pET24a-pro-NK/Q59E- N218D。
PCR product is analyzed and identified by 1.0% agarose gel electrophoresis；It is again that PCR product is pure with DNA purification kits Change, finally use QuichCutTmDpnI digests 5h in 37 DEG C and removes the template plasmid to methylate, is transferred to BL21 escherichia coli hosts, Recombinant bacterium is named as BL21/pET24a-pro-NK/Q59E-N218D.
The structure of 2 Nattokinase Trimutant of embodiment
Using pET24a-pro-NK as masterplate, with primer shown in table 1 under the conditions of shown in table 5, PCR obtains carrying coding The recombinant vector of Q59E mutant genes；Using small amount plasmid extraction kit, upper step extracts pET24a- to specifications Pro-NK/Q59E plasmids, then using pET24a-pro-NK/Q59E as template, with primer shown in table 4 under the conditions of shown in table 5, PCR Obtain carrying coding Q59E-Y217K-N218D Trimutant genes, plasmid is named as pET24a-pro-NK/Q59E-Y217K- N218D。
4 mutant Q59E-Y217K-N218D primers of table
The full plasmid PCR amplification reaction system of table 5
Pcr amplification reaction condition is：
PCR product is analyzed and identified by 1.0% agarose gel electrophoresis；It is again that PCR product is pure with DNA purification kits Change, finally use QuichCutTmDpnI digests 5h in 37 DEG C and removes the template plasmid to methylate, is transferred to BL21 escherichia coli hosts, Recombinant bacterium is named as BL21/pET24a-pro-NK/Q59E-Y217K-N218D.
The expression of 3 Nattokinase mutant of embodiment
(1) by recombination bacillus coli BL21/pET24a-pro-NK/Q59E-Y217K-N218D, BL21/pET24a-pro- NK/Q59E、BL21/pET24a-pro-NK/Y217K、BL21/pET24a-pro-NK/N218D、BL21/pET24a-pro-NK/ Q59E, is inoculated in the LB culture mediums that 5mL kanamycins concentration is 100 μ g/mL, 37 DEG C, 200r/min shaken overnight cultures respectively.
(2) it is 100 μ g/mL's upper seed liquor to be inoculated in concentration containing kanamycins by the inoculum concentration of mass fraction 1% In 100mL TB expression culture mediums, 37 DEG C, 200r/min shaken cultivations to OD600During to 0.6-0.8, derivant IPTG is added extremely 0.1mM, 18 DEG C of induction 20h collect thalline, and bacterium is received in the rotating speed centrifugation of 5000g.
(3) restructuring thalline is dissolved in 20mL combination buffer solutions (50mmol/LNa2HPO4、50mmol/LNaH2PO4、 500mmol/LNaCl, 20mmol/L imidazole), ultrasonication, 13000g centrifugation 25min, 0.22 μm of filter membrane mistake of supernatant Filter.With the combination buffer solution balance columns of 10 times of column volumes, washed with the elution buffer solution of imidazoles containing 20mmol/L of 5 times of column volumes The albumen of non-specific adsorption is removed, then elutes albumen (repeating to elute) with the elution buffer of 50 and 100mmol/L imidazoles respectively, Collect sample and analyzed and identified with SDS-PAGE.
The pH stability analyses of 4 Nattokinase single mutant of embodiment and double-mutant
PH stability determines：By wild enzyme WT, single mutant, double-mutant, Trimutant in 4 in pH4 buffer solutions DEG C retain after 4h in the measure residual enzyme activity of pH 8 time, as shown in Figure 1, discovery is in acid condition, mutant Q59E-Y217K- The wilder enzyme of the stability of N218D and mutant Y217K is improved largely.
The dynamic analysis of 5 Nattokinase single mutant of embodiment and double-mutant
Kinetic constant determines：Using artificial synthesized tetrapeptide suc-AAPF-pNA as substrate, substrate concentration range for 5 × 10-5To 10-3M, using paranitroanilinum as standard, according to the absorption value of 405nm, so as to calculate the enzymatic under each concentration of substrate Reaction rate, then Km and Vmax are obtained by the fittings of software GraphPad Prism 5.Mutant Q59E-Y217K-N218D is urged Change efficiency (kcat/Km) and specific enzyme activity improves 30% or so compared to wild-type enzyme.
The dynamic analysis of 6 enzyme of table
Although the present invention is disclosed as above with preferred embodiment, it is not limited to the present invention, any to be familiar with this skill The people of art, without departing from the spirit and scope of the present invention, can do various change and modification, therefore the protection model of the present invention Enclosing be subject to what claims were defined.
SEQUENCE LISTING
Sequence table
<110>Southern Yangtze University
<120>The Nattokinase that a kind of heat endurance improves
<160> 2
<170> PatentIn version 3.3
<210> 1
<211> 275
<212> PRT
<213>It is artificial synthesized
<400> 1
Ala Gln Ser Val Pro Tyr Gly Ile Ser Gln Ile Lys Ala Pro Ala Leu
1 5 10 15
His Ser Gln Gly Tyr Thr Gly Ser Asn Val Lys Val Ala Val Ile Asp
20 25 30
Ser Gly Ile Asp Ser Ser His Pro Asp Leu Asn Val Arg Gly Gly Ala
35 40 45
Ser Phe Val Pro Ser Glu Thr Asn Pro Tyr Gln Asp Gly Ser Ser His
50 55 60
Gly Thr His Val Ala Gly Thr Ile Ala Ala Leu Asn Asn Ser Ile Gly
65 70 75 80
Val Leu Gly Val Ala Pro Ser Ala Ser Leu Tyr Ala Val Lys Val Leu
85 90 95
Asp Ser Thr Gly Ser Gly Gln Tyr Ser Trp Ile Ile Asn Gly Ile Glu
100 105 110
Trp Ala Ile Ser Asn Asn Met Asp Val Ile Asn Met Ser Leu Gly Gly
115 120 125
Pro Thr Gly Ser Thr Ala Leu Lys Thr Val Val Asp Lys Ala Val Ser
130 135 140
Ser Gly Ile Val Val Ala Ala Ala Ala Gly Asn Glu Gly Ser Ser Gly
145 150 155 160
Ser Thr Ser Thr Val Gly Tyr Pro Ala Lys Tyr Pro Ser Thr Ile Ala
165 170 175
Val Gly Ala Val Asn Ser Ser Asn Gln Arg Ala Ser Phe Ser Ser Val
180 185 190
Gly Ser Glu Leu Asp Val Met Ala Pro Gly Val Ser Ile Gln Ser Thr
195 200 205
Leu Pro Gly Gly Thr Tyr Gly Ala Tyr Asn Gly Thr Ser Met Ala Thr
210 215 220
Pro His Val Ala Gly Ala Ala Ala Leu Ile Leu Ser Lys His Pro Thr
225 230 235 240
Trp Thr Asn Ala Gln Val Arg Asp Arg Leu Glu Ser Thr Ala Thr Tyr
245 250 255
Leu Gly Asn Ser Phe Tyr Tyr Gly Lys Gly Leu Ile Asn Val Gln Ala
260 265 270
Ala Ala Gln
275
<210> 2
<211> 828
<212> DNA
<213>It is artificial synthesized
<400> 2
gcgcaatctg ttccttatgg catttctcaa attaaagcgc cggctcttca ctctcaaggc 60
tacacaggct ctaacgtaaa agtagctgtt atcgacagcg gaattgactc ttctcatcct 120
gacttaaacg tcagaggcgg agcaagcttc gttccttctg aaacaaaccc ataccaggac 180
ggcagttctc acggtacgca tgtcgccggt acgattgccg ctcttaataa ctcaatcggt 240
gttctgggcg tagcgccaag cgcatcatta tatgcagtaa aagtgcttga ttcaacagga 300
agcggccaat atagctggat tattaacggc attgagtggg ccatttccaa caatatggat 360
gttatcaaca tgagccttgg cggacctact ggttctacag cgctgaaaac agtagttgat 420
aaagcggttt ccagcggtat cgtcgttgct gccgcagccg gaaacgaagg ttcatccgga 480
agcacaagca cagtcggcta ccctgcaaaa tatccttcta ctattgcagt aggtgcggta 540
aacagcagca accaaagagc ttcattctcc agcgtaggtt ctgagcttga tgtaatggct 600
cctggcgtgt ccatccaaag cacacttcct ggaggcactt acggcgctta taacggaacg 660
tccatggcga ctcctcacgt tgccggagca gcagcgctaa ttctttctaa gcacccgact 720
tggacaaacg cgcaagtccg tgatcgttta gaaagcactg caacatatct tggaaactct 780
ttctactatg gaaaagggtt aatcaacgta caagcagctg cacaataa 828
<210> 3
<211> 30
<212> DNA
<213>It is artificial synthesized
<400> 3
gaaacaaacc catacgagga cggcagttct 30
<210> 4
<211> 30
<212> DNA
<213>It is artificial synthesized
<400> 4
gtgagaactg ccgtcctcgt atgggtttgt 30
<210> 5
<211> 30
<212> DNA
<213>It is artificial synthesized
<400> 5
ggcacttacg gcgctaagaa cggaacgtcc 30
<210> 6
<211> 32
<212> DNA
<213>It is artificial synthesized
<400> 6
ccatggacgt tccgttctta gcgccgtaag tg 32
<210> 7
<211> 30
<212> DNA
<213>It is artificial synthesized
<400> 7
acttacggcg cttatgacgg aacgtccatg 30
<210> 8
<211> 30
<212> DNA
<213>It is artificial synthesized
<400> 8
cgccatggac gttccgtcat aagcgccgta 30

Claims (10)

1. a kind of stability-enhanced Nattokinase mutant, it is characterised in that it by amino acid sequence is SEQ that the mutant, which is, The 59th of Nattokinase shown in ID NO.1, the 217th, one or more amino acid sites of the 218th are mutated.
2. mutant according to claim 1, it is characterised in that it by amino acid sequence is SEQ ID that the mutant, which is, 217th tyrosine of the Nattokinase shown in NO.1 sports lysine.
3. mutant according to claim 1, it is characterised in that it by amino acid sequence is SEQ ID that the mutant, which is, 59th glutamine of the Nattokinase shown in NO.1 sports glutamic acid, while the 217th tyrosine is sported bad ammonia Acid and 218 asparagine mutations are aspartic acid, obtain combination mutant Q59E-Y217K-N218D.
4. express the recombinant bacterium of any mutant of claim 1-3.
5. the construction method of recombinant bacterium according to claim 4：The gene of Nattokinase mutant is connected to carrier On pET24a, with e. coli bl21 position host, recombinant bacterium is built.
6. the method for recombinant bacterium expression Nattokinase mutant according to claim 4, it is characterised in that the tool of the method Body step is as follows：
(1) recombinant bacterium is inoculated in the LB culture mediums containing kanamycins, 35-38 DEG C, 150-250r/min shaken overnight cultures obtain To seed liquor.
(2) seed liquor is inoculated in the expression culture medium of the concentration containing kanamycins respectively by the inoculum concentration that mass fraction is 1-2% In, 35-38 DEG C, 150-250r/min shaken cultivations to OD600During to 0.6-0.8, derivant IPTG is added, in 15-18 DEG C of induction The expression of 18-24h Nattokinase mutant.
7. the according to the method described in claim 6, it is characterized in that, derivant IPTG to 0.05-0.2mM.
8. according to the method described in claim 6, it is characterized in that, the expression culture medium is TB culture mediums, the TB is cultivated Base component is：Tryptone 10-14g/L, yeast extract 20-26g/L, glycerine 3-8g/L, KH2PO42.0-2.6g/L K2HPO4·3H2O 15.8-16.8g/L, CaCl20.15-0.25g/L, surplus are water.
9. the Nattokinase mutant that the method according to claim 6-8 obtains.
10. the Nattokinase mutant according to right wants 9 is being prepared for treating answering in cardiovascular and cerebrovascular diseases medicament With.
CN201711376850.1A 2017-12-19 2017-12-19 Nattokinase with improved acid resistance Active CN107937372B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711376850.1A CN107937372B (en) 2017-12-19 2017-12-19 Nattokinase with improved acid resistance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711376850.1A CN107937372B (en) 2017-12-19 2017-12-19 Nattokinase with improved acid resistance

Publications (2)

Publication Number Publication Date
CN107937372A true CN107937372A (en) 2018-04-20
CN107937372B CN107937372B (en) 2020-03-24

Family

ID=61942482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711376850.1A Active CN107937372B (en) 2017-12-19 2017-12-19 Nattokinase with improved acid resistance

Country Status (1)

Country Link
CN (1) CN107937372B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112029785A (en) * 2019-06-03 2020-12-04 南开大学 Biological preparation technology of oral hypoglycemic antithrombotic peptide (OHA)
CN114317502A (en) * 2021-12-06 2022-04-12 江南大学 Nattokinase mutant with high activity and high thermal stability
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1052897A (en) * 1989-10-31 1991-07-10 詹伦卡国际有限公司 Subtilisin mutants
KR20060087627A (en) * 2005-01-29 2006-08-03 (주)바이오벤 Novel fibrinolytic protease
CN102943060A (en) * 2012-11-22 2013-02-27 中国农业科学院农产品加工研究所 Strain for nattokinase with high activity and thermal stability and fermented product thereof
CN103255156A (en) * 2013-05-30 2013-08-21 中国农业科学院农产品加工研究所 Site mutant nattokinase gene high in activity and thermal stability, and application thereof
US20150031114A1 (en) * 2012-02-17 2015-01-29 Henkel Ag & Co. Kgaa Detergent compositions comprising subtilase variants

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1052897A (en) * 1989-10-31 1991-07-10 詹伦卡国际有限公司 Subtilisin mutants
KR20060087627A (en) * 2005-01-29 2006-08-03 (주)바이오벤 Novel fibrinolytic protease
US20150031114A1 (en) * 2012-02-17 2015-01-29 Henkel Ag & Co. Kgaa Detergent compositions comprising subtilase variants
CN102943060A (en) * 2012-11-22 2013-02-27 中国农业科学院农产品加工研究所 Strain for nattokinase with high activity and thermal stability and fermented product thereof
CN103255156A (en) * 2013-05-30 2013-08-21 中国农业科学院农产品加工研究所 Site mutant nattokinase gene high in activity and thermal stability, and application thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
MEIZHI WENG ET AL.: "Enhancement of oxidative stability of the subtilisin nattokinase by site-directed mutagenesis expressed in Escherichia coli", 《BIOCHIMICA ET BIOPHYSICA ACTA》 *
MEIZHI WENG ET AL.: "Improving the activity of the subtilisin nattokinase by site-directed mutagenesis and molecular dynamics simulation", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 *
ZHONG-LIANG ZHENG ET AL.: "Probing the importance of hydrogen bonds in the active site of the subtilisin nattokinase by site-directed mutagenesis and molecular dynamics simulation", 《BIOCHEM.J.》 *
ZHONGMEI LIU ET AL.: "Improvement of the acid resistance, catalytic efficiency, and thermostability of nattokinase by multisite‐directed mutagenesis", 《BIOTECHNOLOGY AND BIOENGINEERING》 *
刘中美等: "通过定点突变增强纳豆激酶的热稳定性", 《现代食品科技》 *
刘朔等: "纳豆激酶第36位氨基酸突变对其活性及热稳定性的影响", 《南京农业大学学报》 *
赵菡等: "通过定点突变提高纳豆激酶的酶活及热稳定性", 《食品与发酵工业》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112029785A (en) * 2019-06-03 2020-12-04 南开大学 Biological preparation technology of oral hypoglycemic antithrombotic peptide (OHA)
CN114317502A (en) * 2021-12-06 2022-04-12 江南大学 Nattokinase mutant with high activity and high thermal stability
CN114317502B (en) * 2021-12-06 2023-08-25 江南大学 Nattokinase mutant with high activity and high thermal stability
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Also Published As

Publication number Publication date
CN107937372B (en) 2020-03-24

Similar Documents

Publication Publication Date Title
CN107828765B (en) Keratinase mutant with improved thermal stability and application thereof
CN110358786B (en) Enzyme mutant
CN107937372A (en) The Nattokinase that a kind of acid resistance improves
WO2010053161A1 (en) Modified flavin-adenine-dinucleotide-dependent glucose dehydrogenase
CN112626056B (en) Nitrilase mutant with improved nitrile hydration activity specificity and application thereof
CN108118037A (en) The glucose oxidase mutant that a kind of heat resistance improves
CN113862233A (en) Method for improving acid stability of glucose oxidase, mutant Q241E/R499E, gene and application
CN108753747A (en) A kind of MTSase mutant of thermal stability and trehalose output increased
CN109082419A (en) A kind of 3alpha-Hydroxysteroid dehydrogenase mutant, coding nucleotide sequence and kit
CN109370998B (en) Omega-transaminase mutant I215F with improved catalytic efficiency
CN110055233B (en) MTSase mutant with improved thermal stability and application thereof
CN108118036A (en) Novel grape carbohydrate oxidase mutant
CN111944790B (en) Neutral protease gene, neutral protease, preparation method and application thereof
CN109486780B (en) Omega-transaminase mutant with improved catalytic efficiency
CN107937374A (en) The Nattokinase that a kind of heat endurance improves
CN112175980A (en) Method for improving activity of polymerase large fragment by site-directed mutagenesis and application
CN114317502B (en) Nattokinase mutant with high activity and high thermal stability
CN108753746A (en) A kind of malt oligosaccharide based mycose synthetase mutant that thermal stability improves
JP3727780B2 (en) Leucine aminopeptidase gene, recombinant DNA, and method for producing leucine aminopeptidase
CN108004225A (en) A kind of mutant of the Phenylalanine aminomutase in pantoea agglomerans source
JP4371312B2 (en) Modified sarcosine oxidase, gene thereof, recombinant DNA and method for producing modified sarcosine oxidase
CN108624568B (en) Mutant xanthine dehydrogenase and application thereof
CN106554945B (en) A kind of fructosyl peptide oxidase that thermal stability is high and its encoding gene and purposes
CN106544330B (en) The high fructosyl peptide oxidase of one species specificity and its encoding gene and purposes
CN109136205A (en) A kind of l-amino acid deaminase mutant and preparation method thereof that heat resistance improves

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant